Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 1 institution in 1 country.
Anna EsmanCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0002-5456-7649
Anna CherkashinaCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0001-7970-7495
Konstantin MironovCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0001-8207-9215
Dmitry DubodelovCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0003-3093-5731
Svetlana SalamaikinaCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0002-2517-5048
Anna GolubevaCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0002-8266-0170
Gasan GasanovCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0002-0121-521X
Kamil KhafizovCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0001-5524-0296
Natalya PetrovaCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0003-0166-555X
Evgeniy CherkashinCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0002-3627-6047
Vasiliy AkimkinCentral Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Russian Federation, Novogireevskaya 3a Str., 111123 Moscow, Russia.ORCID 0000-0003-4228-9044
Central Research Institute of Epidemiology · RU
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
According to the temporary recommendations of the 2021 World Health Organization (WHO), in addition to whole-genome sequencing, laboratories in various countries can also screen for known mutations utilizing targeted RT-PCR-based mutation detection assays. The aim of this work was to generate a laboratory technique to differentiate the main circulating SARS-CoV-2 variants in 2021-2022, when a sharp increase in morbidity was observed with the appearance of the Omicron variant. Real-time PCR methodology is available for use in the majority of scientific and diagnostic institutions in Russia, which makes it possible to increase the coverage of monitoring of variants in the territories of all 85 regions in order to accumulate information for the Central Services and make epidemiological decisions. With the methodology developed by the Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (FSSCRP Human Wellbeing) (CRIE), more than 6000 biological samples have been typed, and 7% of samples with the Delta variant and 92% of samples with the Omicron variant have been identified as of 25 August 2022. Reagents for 140,000 definitions have been supplied to regional organizations.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SARS-CoV-2 Variants Monitoring Using Real-Time PCR. · full record | OpenQuestion